Mini reviews in medicinal chemistry · 2026
Medicinal Chemistry of Fourth-generation Tyrosine Kinase Inhibitors.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zayed Mohamed F
Аннотация
UNLABELLED: Introduction / Objectives: Resistance to chemotherapies represents a critical challenge in the treatment of Non-Small Cell Lung Cancer (NSCLC). This clinical imperative drove the discovery of Fourth-Generation Tyrosine Kinase Inhibitors (FGTKIs) to defeat such resistance mechanisms. The study comprehensively reviews and critically analyzes the medicinal chemistry of FGTKIs, focusing on their rational design, mechanisms of action, Structure-Activity Relationships (SARs), and therapeutic potential for overcoming resistance mutations in oncology.
METHODS: A systematic search of major medical databases was conducted to recognize and integrate related literature.
RESULTS: FGTKIs represent a class of structurally efficient anticancer agents that function through the allosteric inhibition of TKs via reversible interactions. This mechanism confers potent inhibitory activity along with improved pharmacokinetic and pharmacodynamic properties.
DISCUSSION: They target the mutant-EGFR to overcome the tertiary resistant mutations (Del19/T790M/C797S), which represent a major clinical challenge against other Tyrosine Kinase Inhibitors (TKIs). They have definite molecular designs and pharmacokinetic properties supporting their action.
CONCLUSION: FGTKIs have altered the therapeutic concept for mutant NSCLC patients and offered unprecedented efficacy and durability compared to earlier-generation inhibitors.
METHODS: A systematic search of major medical databases was conducted to recognize and integrate related literature.
RESULTS: FGTKIs represent a class of structurally efficient anticancer agents that function through the allosteric inhibition of TKs via reversible interactions. This mechanism confers potent inhibitory activity along with improved pharmacokinetic and pharmacodynamic properties.
DISCUSSION: They target the mutant-EGFR to overcome the tertiary resistant mutations (Del19/T790M/C797S), which represent a major clinical challenge against other Tyrosine Kinase Inhibitors (TKIs). They have definite molecular designs and pharmacokinetic properties supporting their action.
CONCLUSION: FGTKIs have altered the therapeutic concept for mutant NSCLC patients and offered unprecedented efficacy and durability compared to earlier-generation inhibitors.